Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (CMMB)

Q: What does CUSIP 16385C203 represent in this 13F holders report?

CUSIP 16385C203 is the security identifier for CMMB - Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share used to aggregate holder disclosures.

Q: How many institutions held CMMB - Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share in Q4 2025?

14 institutional investors reported CMMB - Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share for Q4 2025. Use the holders table for investor-level position and value details.

CUSIP: 16385C203

Q4 2025 13F Holders as of 31 Dec 2025

Security type / class: Equity / Ordinary shares, no par value per share
Total 13F shares: 367,379
Total 13F value: $606,135
Share change: -25,306
SEC-reported price per share: $1.65
Number of holders: 14
Value change: -$247,038
Number of buys: 9
Number of sells: 5
Shares outstanding: 491,982,609

Security key

16385C203

Report period

Q4 2025

Institutions

Top holders

CMMB full security history Ownership snapshot Full 13F holder table Newer quarter: Q1 2026 Previous quarter: Q3 2025 Chemomab Therapeutics Ltd. SEC filings Chemomab Therapeutics Ltd. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 16385C203

Newer quarter: Q1 2026 Previous quarter: Q3 2025

Recent filing periods:

Q2 2026 Q1 2026 Q4 2025 Q3 2025

Ownership snapshot

Top reported holders of CMMB - Chemomab Therapeutics Ltd. - Ordinary shares, no par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

OrbiMed Israel BioFund GP...

Disclosed value leader

Peter Thiel

Comparable rows

12/15

Latest evidence

31 Dec 2025

13D/G 13F 3/4/5 Lead comparable stake: 4.8% 3 rows are not safely comparable across share classes. 13D/G row: OrbiMed Israel BioFund GP Limited Partnership Showing 1-6 of 15 holder rows.

Quick read

OrbiMed Israel BioFund GP Limited Partnership leads the comparable SEC ownership view at 4.8%.

12 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens OrbiMed Israel BioFund GP Limited Partnership's linked filing trail.

Comparable ownership Top 5

OrbiMed Israel BioFund GP Limited... 4.8%

SPHERA FUNDS MANAGEMENT LTD. 4.8%

Peter Thiel 4.6%

MORGAN STANLEY 3.2%

Ikarian Capital, LLC 0.01%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
OrbiMed Israel BioFund GP Limited Partnership	13D/G 13D/G	4.8%	$1,328,636 969,807 shares	$0	18 Jun 2025
SPHERA FUNDS MANAGEMENT LTD.	13D/G 13F Company 13D/G 13F	4.8%	$1,152,548 900,428 shares	$0	31 Mar 2025
Peter Thiel	13D/G 13D/G	4.6%	$40,509,848 22,631,200 shares	$0	31 Dec 2025
MORGAN STANLEY	13D/G 13F Company 13D/G 13F	3.2%	$15,327,382 13,213,260 shares	-$22,120,527	31 Jul 2025
Ikarian Capital, LLC	13F Company 13F	0.01%	$140,079 53,262 shares	—	30 Sep 2025
Stonepine Capital Management, LLC	13F Company 13F	0.01%	$78,900 30,000 shares	—	30 Sep 2025

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

367,379

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2025 holders

Holder diff

Investor	Q3 2025 Shares	Q4 2025 Shares	Share Diff	Share Chg %	Q3 2025 value	Q4 2025 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend